TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics in the Reduction of Antibiotic Associated Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to Good Samaritan Hospital~* Placed on pneumonia order set~* Age 18+~Exclusion Criteria:~* Patient with inadequate coherency to understand consent~* Active Diarrhea at admission~* Non-controlled intestinal disease~* Documented positive C. difficile infection within the 3 months before enrollment~* Antibiotic use at hospital admission~* Immunosuppressive therapy~* Pregnancy~* Allergic to ingredients in Florajen-3~* Allergic to ingredients in placebo~* Immunocompromised state including:~* HIV with a low CD4 count~* Active malignancy receiving chemotherapy~* Medications including long-term steroids (\>2 weeks), and disease modifying biologic agents~* Acquired immune deficiency~* Unable to take oral medication~* Less than 4 doses of probiotic or placebo~* Taking probiotic in the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Probiotic (Type: ACTIVE_COMPARATOR): Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The treatment is Florajen-3. The ingredients in Florajen-3 are:~Lactobacillus acidophilus-over 7.5 billion Bifidobacterium lactis-over 6.0 billion Bifidobacterium longum-over 1.5 billion
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The ingredients in the placebo are:~Rice maltodextrin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* • Diagnosis of Group 1 PAH~  * Either lack of treatment for PAH or sub-optimally treated PAH as defined by NYHA FC 3 or 4~ * Age 18 or older~ * Ability to give consent~ * Ability to undergo overnight polysomnogram~ * Previously diagnosed OSA not on therapy~Exclusion Criteria:~* Age younger than 18~* Pregnancy~* Previously diagnosed OSA and receiving therapy~* Inability to undergo overnight polysomnography in laboratory

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Closed-loop Anesthesia in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* class ASA I, II or III~* general anesthesia scheduled to last more than one hour~* intraoperative hemorrhage planned to be less than 15% of the blood volume~Exclusion Criteria:~* Combined general and regional anesthesia,~* Patients with a pacemaker or scheduled for a cardiac or brain surgical procedure,~* History of a neurological or a psychiatric disorder, or central brain lesion,~* Patients receiving a psychotropic treatment or a a morphine agonist-antagonist,~* Allergy to latex, propofol, remifentanil, morphine, muscle relaxant, or to a component,~* Hypersensibility to remifentanil or to a derivate of fentanyl,~* Scheduled postoperative ventilation or sedation.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): closed-loop administration of propofol and remifentanil using bispectral index as the controller
- 2 (Type: ACTIVE_COMPARATOR): manual administration of propofol and remifentanil according to bispectral index values

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers, either with PCOS/PCOS-like ovaries, or with normal ovaries, who undergo oocyte donation for research~* AFC at least 10~* AMH: \> 5 μg/L~* Female age \< 36 years~Exclusion Criteria:~* major uterine or ovarian abnormalities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- in-vitro maturation of oocytes (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient's parent or legal representative has provided informed consent~2. Must be receiving medical care in an intensive care unit~3. Age less than 18 years.~4. Body weight between ≥10 and ≤ 20 kilograms~5. Intent to receive full supportive care through aggressive management~6. Clinical diagnosis of AKI requiring CRRT~7. At least one non-renal organ failure OR presence of proven/suspected sepsis~Exclusion Criteria:~1. Threshold blood pressure of 80/40 mmHg~2. Patients with a solid organ transplant or those with a bone marrow or stem cell transplant in the previous 100 days or who have not engrafted~3. Acute or chronic use of circulatory support device, other than extracorporeal membrane oxygenation (ECMO)~4. Presence of preexisting advanced chronic renal failure on chronic renal replacement therapy or with an estimated glomerular filtration rate less than 30 mL/min/1.73m2~5. AKI occurring in the setting of burns, obstructive uropathy, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, cyclosporine or tacrolimus nephrotoxicity~6. Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy~7. Chronic immunosuppression with the exception of corticosteroids up to a dose of 10 mg of prednisone per day~8. Known positive HIV or AIDS or COVID-19~9. Current Do not Attempt Resuscitation (DNAR), Allow Natural Death (AND), or withdrawal of care status, or anticipated change in status within the next 7 days~10. Patient not expected to survive 28 days because of an irreversible medical condition~11. Any medical condition that the Investigator thinks may interfere with the study objectives~12. Treating clinician does not feel it is in the best interest of the patient~13. Platelet count \<15,000/mm3~14. Concurrent enrollment in another interventional clinical trial~15. Use of any other investigational drug or device within the previous 30 days~16. Use of AN-69 hemofilter membrane for CRRT

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SCD Treatment (Type: OTHER): Pediatric patients receiving SCD + CRRT for up to 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Does Pulse-triggered VNS Autostimulation Increase VNS Efficacy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects, 12 years of age or older, who have a VNS without ECG-triggered auto stimulation implanted, have a positive effect and have a device replacement with model 106 or model 1000 due to low battery capacity,.~* Subjects, who have 2 or more seizure per month and not more than 28 days between seizures during the baseline.~* Subjects, who are on a stable regiment of antiepileptic drug treatment for at least 3 month prior to enrollment and maintain on this regimen throughout the study.~* VNS parameters have not been changed I the last 3 month prior to enrollment.~* Subjects which are using an off time of at least 1.8 min. (If the patient is on a duty cycle involving an off-time of 1.1 min. or less, and willing to participate in the study the duty cycle will have to be changed to fulfill the inclusion criteria as follows. The off-time will be changed to 1.8 min. and the on-time accordingly to achieve about the same duty cycle as the patient had before. If the duty cycle is above 30% the parameters will be changed to 60 sec./1.8 min., if the duty cycle is between 30% and 23% the parameters will be change to 30 sec./1,8 min., if the duty cycle is 20% the parameters will be change to 21 sec./1,8 min. and if the duty cycle is 15% the parameters will be change to 14 sec./1,8 min. After at periode of 3 month observation the patient can be included in the study.)~* Either the subjects or the legal guardian are able to agree to participate by signing the informed consent form.~Exclusion Criteria:~* Subjects with rapidly progressive neurodegenerative or rapidly progressing neoplastic disease.~* Subjects or legal guardians who are unable to understand the study procedures.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DEB-TACE for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older, inclusive~* Diagnosis of HCC~* Meets UCSF criteria: a single lesion less than or equal to 6.5 cm in diameter or 2-3 lesions less than or equal to 4.5 cm with total tumor diameter less than or equal to 8 cm.~* No portal invasion or extrahepatic spread on imaging.~* Child-Pugh Class A or B.~* No previous chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy).~* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* A discrete hepatic artery feeding the tumor with diameter of the vessels equal to or greater than 1.5 mm.~Exclusion Criteria:~* Bilirubin levels greater than 3 mg/dl~* AST or ALT greater than 5 times upper limit of normal or greater than 250 U/l.~* Advanced tumoral disease (vascular invasion or extrahepatic spread, portal vein thrombosis of bland or malignant origin), or diffuse HCC, defined as 50% liver involvement).~* Contraindications for doxorubicin administration.~* Subject has a known history contraindicating contrast dye or iodine that cannot be safely controlled via antihistamine, steroids, or with any other agent.~* Unable or unwilling to provide informed consent.~* Vessels providing flow to the tumor that are less than 1.5 mm in diameter.~* Women who are pregnant or breast feeding.~* Women of childbearing potential who are not using an acceptable method of birth control (e.g., pill, patch, IUD, ring, condom, sponge, foam).~* Portal vein thrombosis of bland or malignant origin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DEB-TACE: Standard Endhole Catheter (Type: ACTIVE_COMPARATOR): Subjects will undergo DEB-TACE using a standard endhole catheter.
- DEB-TACE: Surefire Infusion System (Type: ACTIVE_COMPARATOR): Subjects will undergo DEB-TACE using the Surefire Infusion System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with either breast or gynecological cancer~* Receiving either AC-like or CT MEC~* Experienced at least 1 episode of vomiting or retching during the first 5 days following Cycle 1 of chemotherapy that was thought to be due to chemotherapy. Received standard chemotherapy-induced nausea and vomiting (CINV) prophylaxis not containing aprepitant or fosaprepitant~* No change in chemotherapy at Cycle 2~* No change in Cycle 1 antiemetic regimen at Cycle 2~* Eastern Cooperative Oncology Group (ECOG) status 0-1~Exclusion Criteria:~* Requires increase in systemic corticosteroid therapy~* Used benzodiazepines or opiates in the 48 hours prior to Cycle 2 chemotherapy~* Received or will receive radiation therapy to the abdomen or pelvis in the week prior to Visit 1 or in Days 1-6 following chemotherapy~* Vomited in the 24 hours prior to Treatment Day 1~* Pregnant or breast-feeding~* Participating in a study with aprepitant or fosaprepitant or has taken an investigational drug in the last 4 weeks~* Symptomatic central nervous system metastasis~* History of other malignancies in the last 2 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fosaprepitant 150 mg (Type: EXPERIMENTAL): Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Outpatient vs. Inpatient Management of Low-risk Patients With Upper Gastrointestinal Bleeding.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Blood Urea Nitrogen \< 18.2 mg/dl~2. Hemoglobin ≥ 13.0 g/dl for men and ≥ 12.0 g/dl for women~3. Systolic blood pressure ≥ 110 mm Hg~4. Heart rate \< 100 beats/min~Exclusion Criteria:~1. Inability to obtain informed consent~2. Pregnancy~3. History of liver disease~4. History of heart failure~5. Syncope that is temporally related to ongoing bleeding~6. Melena~7. Contraindication to proton pump inhibitor use~8. Other conditions that necessitate inpatient evaluation.~9. Inpatients with new onset of GI bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Outpatient (Type: ACTIVE_COMPARATOR): None
- Inpatient (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evolution of Dark Ideas When Introducing or Switching an Antidepressant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Subject aged 18 to 65~* Diagnosis of a characterized depressive episode assessed by the clinician~* Depression score : MADRS\> 20~* Introduction or switch of an antidepressant (without combination of molecules)~* Signed informed consent~* Able to understand the nature, purpose and methodology of the study~* French language~* Able to understand and conduct clinical assessments.~Exclusion criteria:~* The following psychiatric comorbidities: Bipolar disorder, schizophrenia, alcohol dependence and / or any other substance objectivized during the clinical evaluation~* Patient presenting a depressive episode characterized with mixed component, psychotic, melancholic or catatonic characteristics~* Score MADRS greater than or equal to 5 to one of the items~* Subject protected by law (guardianship or curatorship)~* Subject in exclusion period from another protocol~* Subject not affiliated to, or not beneficiary of, a social security scheme~* Pregnant orbreastfeeding patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- depressed patients (Type: OTHER): All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits.~All patients are depressed patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Any patient above age 18, with measurable metastatic melanoma or other solid tumor, with at least one tumor deposit that is easily accessible to peri-tumoral DC injection. The preferred location is subcutaneous or intradermal. Patients with additional metastatic sites will not be excluded. Patients should have an expected survival of greater than three months.~   Patient must have received accepted standard treatment of his or her cancer:~  * for melanoma - DTIC -containing protocol ,unless unwilling. Previous treatment with IL-2 is not an excluding factor.~  * for breast cancer - adriamycin and cyclophosphamide, taxanes, and vinorelbine-containing protocols~  * for lung, renal and GIT cancers- one previous chemotherapy line~2. Serum creatinine of 2.0 mg/dl or less.~3. Total bilirubin 1.6 mg/dl or less, except for patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.~4. WBC 3000/mm3 or greater.~5. Platelet count 90,000 mm3 or greater.~6. Serum AST/ALT less then two times normal.~7. ECOG performance status of 0, 1 or 2.~8. Patients of both genders must be willing to practice effective birth control during this trial.~9. Patient agreed to participate in the study and has signed a written informed consent.~Exclusion Criteria:~Patients will be excluded:~1. who are undergoing or have undergone in the past 3 weeks any other form of therapy except from surgery for their cancer.~2. have active systemic infections, coagulation disorders, autoimmune disease or other major medical illnesses of the cardiovascular or respiratory systems or any known immunodeficiency disease.~3. who require steroid therapy.~4. who are pregnant (because of possible side effects on the fetus).~5. who are known to be positive for hepatitis B and C or HIV antibody (because of possible immune effects of these conditions).~6. who have any form of primary or secondary immunodeficiency. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)~7. who are allergic to eggs.~i. who have an active major medical illnesses such as cardiac ischemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Antibiotic Therapy for Pyelonephritis in Childhood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 1 month to 5 years, with a first episode of pyelonephritis.~Exclusion Criteria:~* Children less than 1 month, or older than 5 years.~* Relapse of pyelonephritis.~* Sepsis and/or vomiting, or other conditions where it's impossible to administer an oral therapy.~* Allergy to ceftibuten.~* Previous antibiotic therapy for the same infection.~* Long term antibiotic prophylaxis with an antibiotic of the same class, if laboratory antibiotic resistance is shown.~* Children with uncontrolled other disease.~* Complicated pyelonephritis (abscess).

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy